As attached.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals reported unaudited financial results for Q2 FY26 and the half-year ended September 30, 2025. Revenue from operations for Q2 FY26 stood at ₹1,126.85 lakhs, more than doubling from ₹555.52 lakhs in the year-ago quarter — a growth of about 103% YoY. Total income for the quarter reached ₹1,405.08 lakhs, and profit after tax also rose sharply compared to Q2 FY25. For the half-year, profit after tax stood at ₹167.16 lakhs, with operating cash flow remaining healthy at ₹301.83 lakhs. The statutory auditors (Shah Sanghvi & Associates) issued an unqualified review opinion on the results. The company continues to operate in a single segment.
A doubling of quarterly revenue is a strong positive signal for business momentum, which may support the stock price in the short term. However, expenses grew faster than revenue, causing EBITDA margins to compress from about 34% in Q2 FY25 to roughly 26% in Q2 FY26 — shareholders should watch whether margin pressure eases in upcoming quarters.